Combipatch side effects, by duration, gender and age (a phase IV clinical study of FDA data)
Summary:
Side effects are reported by people who take Combipatch (estradiol; norethindrone acetate). Common side effects include breast cancer among females and breast cancer among males.
The phase IV clinical study is created by eHealthMe based on 3,544 reports from the FDA, and is updated regularly.
What is Combipatch?
Combipatch has active ingredients of estradiol; norethindrone acetate. It is often used in menopause. eHealthMe is studying from 3,599 Combipatch users. Check the latest studies of Combipatch.
3,544 people who take Combipatch and have side effects are studied.
What are the common side effects of Combipatch, by gender? *
What are the common side effects of Combipatch, by age (0-1 to 60+)? *
What are the common side effects of Combipatch, by the time people have been on the drug (< 1 month to 10+ years)? *
* Approximation only. Some reports may have incomplete information.
Do you take Combipatch?
- Personalize this study to your gender and age- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
How the study uses the data?
The study is based on estradiol; norethindrone acetate (the active ingredients of Combipatch) and Combipatch (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.
Related studies are listed below in case you need more information:
Alternative drugs to, pros and cons of Combipatch:
- Combipatch (3,599 reports)
All Combipatch side effects from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zWho is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Tobi cause Secretion Discharge? - a second ago
- Drug interactions of Enoxaparin Sodium and Progesterone - 2 seconds ago
- Symbicort and Low Thyroid for Women aged 60+ - 4 seconds ago
- Symbicort and Under Active Thyroid for Women aged 60+ - 4 seconds ago
- Symbicort and Hypothyroids for Women aged 60+ - 4 seconds ago
- Symbicort and Under Active Thyroids for Women aged 60+ - 5 seconds ago
- Symbicort and Underactive Thyroid for Women aged 60+ - 5 seconds ago
- Symbicort and Hypothyroidy for Women aged 60+ - 5 seconds ago
- Could Xarelto cause Breast Pain? - 5 seconds ago
- Symbicort and Hypothyroid for Women aged 60+ - 6 seconds ago